{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:27:04Z","timestamp":1787243224579,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019054","name":"Changsha Science and Technology Project","doi-asserted-by":"publisher","award":["KQ2004130"],"award-info":[{"award-number":["KQ2004130"]}],"id":[{"id":"10.13039\/501100019054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170192"],"award-info":[{"award-number":["82170192"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303190"],"award-info":[{"award-number":["82303190"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.isci.2025.113053","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T17:42:41Z","timestamp":1751564561000},"page":"113053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Interferon-\u03b1 and thymosin-\u03b11 plus tislelizumab enhance CD8+ T cell cytotoxicity toward pancreatic ductal adenocarcinoma"],"prefix":"10.1016","volume":"28","author":[{"given":"Shun","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rilin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biaoming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhai","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizhen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0835-7464","authenticated-orcid":false,"given":"Chaohui","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2025.113053_bib1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12916-018-1215-3","article-title":"Pancreatic cancer: challenges and opportunities","volume":"16","author":"Zhu","year":"2018","journal-title":"BMC Med."},{"key":"10.1016\/j.isci.2025.113053_bib2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","volume":"67","author":"Mace","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.isci.2025.113053_bib3","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.isci.2025.113053_bib4","first-page":"318","article-title":"Recent progress in pancreatic cancer","volume":"63","author":"Wolfgang","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.isci.2025.113053_bib5","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.113053_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12935-019-0798-x","article-title":"Overexpression and Tyr421-phosphorylation of cortactin is induced by three-dimensional spheroid culturing and contributes to migration and invasion of pancreatic ductal adenocarcinoma (PDAC) cells","volume":"19","author":"Stock","year":"2019","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.isci.2025.113053_bib7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.isci.2025.113053_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173240","article-title":"Regulation of PD-1 in T cells for cancer immunotherapy","volume":"881","author":"Yu","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.isci.2025.113053_bib9","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41423-020-00549-9","article-title":"The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt\/beta-catenin signaling pathway","volume":"17","author":"Deng","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.isci.2025.113053_bib10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.semcancer.2021.04.002","article-title":"Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy","volume":"85","author":"Dai","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.isci.2025.113053_bib11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41416-018-0298-0","article-title":"Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer","volume":"120","author":"Gao","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.isci.2025.113053_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109533","article-title":"ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21\/AKT\/beta-catenin\/PD-L1 axis","volume":"27","author":"Deng","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.isci.2025.113053_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108414","article-title":"Helicobacter pylori CagA promotes immune evasion of gastric cancer by upregulating PD-L1 level in exosomes","volume":"26","author":"Wang","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.isci.2025.113053_bib14","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1186\/s12885-019-6145-8","article-title":"IFN-\u03b3 down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer","volume":"19","author":"Ding","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.isci.2025.113053_bib15","article-title":"Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma","volume":"4","author":"Duan","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2025.113053_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030738","article-title":"Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2025.113053_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101480","article-title":"Emerging concepts in PD-1 checkpoint biology","volume":"52","author":"Pauken","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.isci.2025.113053_bib18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40265-020-01286-z","article-title":"Tislelizumab: First Approval","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.isci.2025.113053_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000062","article-title":"PD-1\/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors","volume":"38","author":"Soares","year":"2015","journal-title":"J. Immunother."},{"key":"10.1016\/j.isci.2025.113053_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105797","article-title":"PZR suppresses innate immune response to RNA viral infection by inhibiting MAVS activation in interferon signaling mediated by RIG-I and MDA5","volume":"222","author":"Deng","year":"2024","journal-title":"Antiviral Res."},{"key":"10.1016\/j.isci.2025.113053_bib21","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2025.113053_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1249330","article-title":"Combining PD-1\/PD-L1 blockade with type I interferon in cancer therapy","volume":"14","author":"Razaghi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.113053_bib23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1196\/annals.1415.039","article-title":"Thymosin alpha1: a historical overview","volume":"1112","author":"Garaci","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.isci.2025.113053_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14712598.2018.1484447","article-title":"From thymus to cystic fibrosis: the amazing life of thymosin alpha 1","volume":"18","author":"Garaci","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.isci.2025.113053_bib25","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1093\/cid\/ciaa630","article-title":"Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells","volume":"71","author":"Liu","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.isci.2025.113053_bib26","doi-asserted-by":"crossref","first-page":"10374","DOI":"10.1021\/acsomega.0c00220","article-title":"Modified Thymosin Alpha 1 Distributes and Inhibits the Growth of Lung Cancer in Vivo","volume":"5","author":"Peng","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.isci.2025.113053_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/14712598.2018.1474198","article-title":"Deciphering cellular biological processes to clinical application: a new perspective for T\u03b11 treatment targeting multiple diseases","volume":"18","author":"Matteucci","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.isci.2025.113053_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107829","article-title":"Combination of Gemcitabine and Thymosin alpha 1 exhibit a better anti-tumor effect on nasal natural killer\/T-cell lymphoma","volume":"98","author":"Chen","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.isci.2025.113053_bib29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1749-6632.2010.05475.x","article-title":"Preclinical studies with IRX-2 and thymosin alpha1 in combination therapy","volume":"1194","author":"Naylor","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.isci.2025.113053_bib30","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1517\/14712598.2015.1008446","article-title":"Evaluation of thymosin \u03b1 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis","volume":"15","author":"King","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.isci.2025.113053_bib31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","article-title":"Therapeutic developments in pancreatic cancer: current and future perspectives","volume":"15","author":"Neoptolemos","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.isci.2025.113053_bib32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-018-0858-1","article-title":"Tumor microenvironment participates in metastasis of pancreatic cancer","volume":"17","author":"Ren","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.isci.2025.113053_bib33","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and Opportunities for Pancreatic Cancer Immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2025.113053_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-018-0578-4","article-title":"Lessons learned from the blockade of immune checkpoints in cancer immunotherapy","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2025.113053_bib35","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1158\/1078-0432.CCR-19-0081","article-title":"Mobilization of CD8(+) T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer","volume":"25","author":"Seo","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.113053_bib36","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.isci.2025.113053_bib37","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1007\/s00432-020-03332-5","article-title":"Immunological combination treatment holds the key to improving survival in pancreatic cancer","volume":"146","author":"Sodergren","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.113053_bib38","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.113053_bib39","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.canlet.2015.12.020","article-title":"Current progress in immunotherapy for pancreatic cancer","volume":"381","author":"Foley","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.isci.2025.113053_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9040373","article-title":"Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment","volume":"9","author":"Javadrashid","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.isci.2025.113053_bib41","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1073\/pnas.1920413117","article-title":"Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8(+) T cell stemness and antitumor immunity","volume":"117","author":"Hermans","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.113053_bib42","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.113053_bib43","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.113053_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.113053_bib45","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","article-title":"Interferons \u03b1 and \u03b2 in cancer: therapeutic opportunities from new insights","volume":"18","author":"Borden","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.isci.2025.113053_bib46","article-title":"Exogenous non-coding dsDNA-dependent trans-activation of phagocytes augments anti-tumor immunity","volume":"5","author":"Delaunay","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2025.113053_bib47","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000052489","article-title":"Interferon-alpha suppresses the antiapoptotic effect of NF-kB and sensitizes renal cell carcinoma cells in vitro to chemotherapeutic drugs","volume":"39","author":"Steiner","year":"2001","journal-title":"Eur. Urol."},{"key":"10.1016\/j.isci.2025.113053_bib48","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3389\/fonc.2019.00873","article-title":"A Reappraisal of Thymosin Alpha1 in Cancer Therapy","volume":"9","author":"Costantini","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2025.113053_bib49","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1749-6632.2012.06697.x","article-title":"Thymosin \u03b11 and cancer: action on immune effector and tumor target cells","volume":"1269","author":"Garaci","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.isci.2025.113053_bib50","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1038\/d41586-017-08702-7","article-title":"The benefits of immunotherapy combinations","volume":"552","author":"Schmidt","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.113053_bib51","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41423-022-00848-3","article-title":"The combination of PD-1 blockade with interferon-alpha has a synergistic effect on hepatocellular carcinoma","volume":"19","author":"Zhu","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.isci.2025.113053_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109829","article-title":"Immunological effects of heated intraperitoneal chemotherapy can be augmented by thymosin alpha1","volume":"116","author":"Nevo","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.isci.2025.113053_bib53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/IPH-100102569","article-title":"Restoration of immunocyte functions by thymosin alpha1 in cyclophosphamide-induced immunodeficient mice","volume":"23","author":"Ohmori","year":"2001","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.isci.2025.113053_bib54","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1386-6346(02)00145-6","article-title":"Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B","volume":"24","author":"Sugahara","year":"2002","journal-title":"Hepatol. Res."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225013148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225013148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:18:48Z","timestamp":1777634328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004225013148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2589004225013148"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2025.113053","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon-\u03b1 and thymosin-\u03b11 plus tislelizumab enhance CD8+ T cell cytotoxicity toward pancreatic ductal adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2025.113053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"113053"}}